Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
FAK inhibitors in cancer, a patent review – an update on progress41
Recent developments of agents targeting Vibrio cholerae : patents and literature data41
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)39
Malaria transmission blocking compounds: a patent review36
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)36
Update on mGlu4 modulator patents: 2017 to present35
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities34
The role of patent analysis in target selection29
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)29
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present28
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)28
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review28
Caspase inhibitors: a review on recently patented compounds (2016–2023)27
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)25
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)24
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
A patent review of MAPK inhibitors (2018 – present)22
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)22
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202321
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201321
Inhibition of GTPase KRAS G12D : a review of patent literature20
EOTP-2025-ST-0028.R1Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)20
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
Antiprotozoal drugs: challenges and opportunities20
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review19
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)19
Small-molecule RNA ligands: a patent review (2018–2024)18
PDE1 inhibitors: a review of the recent patent literature (2008-present)18
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)18
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)16
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders15
A patent review of IDH1 inhibitors (2018-present)15
Antimalarial drugs: what’s new in the patents?15
An updated patent review of MALT1 inhibitors (2021–present)15
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)15
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)15
Biofilm and bacterial membrane vesicles: recent advances14
Dopamine D3 receptor ligands: a patent review (2014–2020)14
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)14
A patent and literature review of CDK12 inhibitors14
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review13
An updated patent review of EZH2 inhibitors (2024–present)13
Are patents important indicators of innovation for Chagas disease treatment?13
An updated patent review on drugs for the treatment of tuberculosis (2018-present)13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
An updated patent review of TRPA1 antagonists (2020 – present)11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
The patent review of the biological activity of tropane containing compounds11
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
Correction10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
A patent review of BRD4 inhibitors (2020–present)10
A patent review of selective CDK9 inhibitors in treating cancer9
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)9
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published9
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress9
Rho kinase inhibitors: a patent review (2017–2023)9
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)9
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)9
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)9
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)9
Patent landscape of small molecule inhibitors of METTL3 (2020-present)9
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)9
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)8
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)8
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)8
A patent review of CXCR7 modulators (2019-present)8
A patent perspective of antiangiogenic agents8
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update7
Nurr1 modulators – a patent review (2019–present)7
An updated patent review on monoamine oxidase (MAO) inhibitors7
A patent review of xanthine oxidase inhibitors (2021–present)7
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)7
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid7
Recent advances in the development of STING inhibitors: an updated patent review7
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents7
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective7
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
Therapeutic cysteine protease inhibitors: a patent review (2018–present)7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Pitfalls in patenting academic CAR-T cells therapy7
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)7
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)7
An updated patent review of Mcl-1 inhibitors (2020–2022)6
Proteasome inhibitors as anticancer agents6
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)6
Natural products as a source of new anticancer chemotypes6
Anticancer drugs: where are we now?6
An updated patent review of BRD4 degraders6
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)6
An updated patent review of glutaminase inhibitors (2019–2022)6
A review of the patent literature surrounding TRPV1 modulators6
An updated patent review of stimulator of interferon genes agonists (2021 – present)6
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)6
Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)5
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)5
BET inhibitors: an updated patent review (2018–2021)5
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)5
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021–2024)5
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections5
A patent review of CHK1 inhibitors (2019 – present)5
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)5
A patent review of MLKL modulators (2023 – present)5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
A patent review of adenosine A2Breceptor antagonists (2016-present)5
1.9321150779724